Immunovaccine Inc. develops cancer immunotherapies and infectious disease vaccines based on the Company’s DepoVax™ platform, a patented formulation that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 2 study with its lead cancer vaccine therapy, DPX-Survivac, in recurrent lymphoma. DPX-Survivac is expected to enter additional Phase 2 clinical studies in ovarian cancer and glioblastoma (brain cancer).  The Company is also advancing an infectious disease pipeline including innovative vaccines for respiratory syncytial virus (RSV), and anthrax.

Analyst Coverage:
Immunovaccine Inc. is followed by the analyst listed below. Please note that any opinions, estimates or forecasts regarding Immunovaccine’s performance made by the analyst are theirs alone and do not represent opinions, forecasts or predictions of Immunovaccine Inc. or its Management.

Echelon Wealth Partners
Douglas W. Loe, PhD, MBA
Office: (416) 775-1004

Maxim Group
Jason McCarthy, Ph.D.
Office: (212) 895-3556

Mackie Research Capital Corporation
Andre Uddin, Ph.D.

Office: (416) 760-8675

Corporate Presentation:
To download Immunovaccine's most recent corporate presentation click here 
Immunovaccine Updates:
Click below to sign up for Immunovaccine press releases and newsletters

SEDAR Filings
To access Immunovaccine’s SEDAR filings, please visit: 

What's New